Rectal cancer, version 2.2015: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 6, 2015, Pages 719-728

  Benson, Al B ^a   Venook, Alan P ^b   Bekaii Saab, Tanios ^c   Chan, Emily ^d   Chen, Yi Jen ^e   Cooper, Harry S ^f   Engstrom, Paul F ^f   Enzinger, Peter C ^g   Fenton, Moon J ^h   Fuchs, Charles S ^g   Grem, Jean L ⁱ   Grothey, Axel ^j   Hochster, Howard S ^k   Hunt, Steven ^l   Kamel, Ahmed ^m   Kirilcuk, Natalie ⁿ   Leong, Lucille A ^e   Lin, Edward ^o   Messersmith, Wells A ^p   Mulcahy, Mary F ^a   Murphy, James D ^q   Nurkin, Steven ^r   Rohren, Eric ^s   Ryan, David P ^t   Saltz, Leonard ^u   Sharma, Sunil ^v   Shibata, David ^w   Skibber, John M ^s   Sofocleous, Constantinos T ^u   Stoffel, Elena M ^x   Stotsky Himelfarb, Eden ^y   Willett, Christopher G ^z   Gregory, Kristina M ^aa   Freedman Cass, Deborah ^aa   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g Dana Farber Brigham and Women's Cancer Center   (United States)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^j MAYO CLINIC CANCER CENTER   (United States)

^k YALE CANCER CENTER   (United States)

^l BARNES JEWISH HOSPITAL   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ STANFORD CANCER INSTITUTE   (United States)

^o SEATTLE CANCER CARE ALLIANCE   (United States)

^p University of Colorado Cancer Center   (United States)

^q UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^r ROSWELL PARK CANCER INSTITUTE   (United States)

^s UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^t MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^u MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^v UNIVERSITY OF UTAH   (United States)

^w H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^x UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^y JOHNS HOPKINS UNIVERSITY   (United States)

^z DUKE CANCER INSTITUTE   (United States)

^aa National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; DISEASE SURVEILLANCE; GASTROENTEROLOGIST; HUMAN; INDUCTION CHEMOTHERAPY; LOCAL RECURRENCE FREE SURVIVAL; LOCALIZED RECTAL CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; SURVIVAL RATE; TUMOR REGRESSION; MULTIMODALITY CANCER THERAPY; RECTAL NEOPLASMS;

COMBINED MODALITY THERAPY; HUMANS; PRACTICE GUIDELINES AS TOPIC; RECTAL NEOPLASMS;

EID: 84932133656     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0087     Document Type: Article

References (38)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104-117.
3. Cheng L, Eng C, Nieman LZ, et al. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011;34:573-580.
4. Henley SJ, Singh S, King J, et al. Invasive cancer incidence - United States, 2010. MMWR Morb Mortal Wkly Rep 2014;63:253-259.
5. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
6. Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2014:1-6.
7. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93:583-596.
8. Rajput A, Bullard Dunn K. Surgical management of rectal cancer. Semin Oncol 2007;34:241-249.
9. Weiser MR, Landmann RG, Wong WD, et al. Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum 2005;48:1169-1175.
10. Wiig JN, Larsen SG, Giercksky KE. Operative treatment of locally recurrent rectal cancer. Recent Results Cancer Res 2005;165:136-147.
11. Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007;25:1014-1020.
12. Cercek A, Goodman KA, Hajj C, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw 2014;12:513-519.
13. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668-674.
14. Fernandez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010;28:859-865.
15. Marechal R, Vos B, Polus M, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol 2012;23:1525-1530.
16. Nogue M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 2011;16:614-620.
17. Perez K, Safran H, Sikov W, et al. Complete neoadjuvant treatment for rectal cancer: the Brown University Oncology Group CONTRE study [published online ahead of print November 14, 2014]. Am J Clin Oncol, in press.
18. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-1123.
19. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-3116.
20. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704.
21. Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014;15:1245-1253.
22. Rodel C, Liersch T, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: results of the German CAO/ARO/AIO-04 randomized phase III trial [abstract]. J Clin Oncol 2014;32:Abstract 3500.
23. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 2014;32:513-518.
24. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240:711-717; discussion 717-718.
25. Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified? Dis Colon Rectum 2008;51:10-19; discussion 19-20.
26. Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011;29:4633-4640.
27. Habr-Gama A, Gama-Rodrigues J, Sao Juliao GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 2014;88:822-828.
28. Glynne-Jones R, Hughes R. Critical appraisal of the 'wait and see' approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg 2012;99:897-909.
29. Dickman R, Kundel Y, Levy-Drummer R, et al. Restaging locally advanced rectal cancer by different imaging modalities after preoperative chemoradiation: a comparative study. Radiat Oncol 2013;8:278.
30. van der Paardt MP, Zagers MB, Beets-Tan RG, et al. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology 2013;269:101-112.
31. Zhao RS, Wang H, Zhou ZY, et al. Restaging of locally advanced rectal cancer with magnetic resonance imaging and endoluminal ultrasound after preoperative chemoradiotherapy: a systemic review and meta-analysis. Dis Colon Rectum 2014;57:388-395.
32. Guillem JG, Ruby JA, Leibold T, et al. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg 2013;258:289-295.
33. Hanly AM, Ryan EM, Rogers AC, et al. Multicenter Evaluation of Rectal cancer ReImaging pOst Neoadjuvant (MERRION) Therapy. Ann Surg 2014;259:723-727.
34. Kuo LJ, Chiou JF, Tai CJ, et al. Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy? Int J Colorectal Dis 2012;27:613-621.
35. Tranchart H, Lefevre JH, Svrcek M, et al. What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer? Ann Surg Oncol 2013;20:1551-1559.
36. Taylor FG, Quirke P, Heald RJ, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts diseasefree survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014;32:34-43.
37. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12:575-582.
38. Guyot F, Faivre J, Manfredi S, et al. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol 2005;16:756-761.